Emerging Infectious Diseases (Dec 2023)

Treatment of Mpox with Suspected Tecovirimat Resistance in Immunocompromised Patient, United States, 2022

  • Caitlin A. Contag,
  • Leah Mische,
  • Isabel Fong,
  • Abraar Karan,
  • Akanksha Vaidya,
  • David W. McCormick,
  • William Bower,
  • Jill K. Hacker,
  • Kelly Johnson,
  • Perla SanJuan,
  • Linda Crebbin,
  • Caroline Temmins,
  • Harleen Sahni,
  • Yael Bogler,
  • Joseph D. Cooper,
  • Supriya Narasimhan

DOI
https://doi.org/10.3201/eid2912.230849
Journal volume & issue
Vol. 29, no. 12
pp. 2520 – 2523

Abstract

Read online

Reports of tecovirimat-resistant mpox have emerged after widespread use of antiviral therapy during the 2022 mpox outbreak. Optimal management of patients with persistent infection with or without suspected resistance is yet to be established. We report a successfully treated case of severe mpox in California, USA, that had suspected tecovirimat resistance.

Keywords